Zoetis Inc.
ZTSNYSEAlpha Score of 30 reflects weak overall profile with poor momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Zoetis Inc. Faces Valuation Pressure Amidst Moderate Revenue Growth Trends
Apr 15, 2026Zoetis Inc. (ZTS) continues to navigate a challenging valuation environment as the stock trades within its 52-week range of $113.35 to $170.30. The company currently commands a P/E ratio of 39.32, which remains elevated relative to its recent performance metrics. While revenue growth remains modest at 2.3% year-over-year, the firm demonstrates operational efficiency with a net margin of 28.2% and a solid EPS growth rate of 10.2%, bringing EPS to $3.08. These figures are reflected in the Alpha Score of 35.5, which is heavily supported by a quality sub-score of 57.4. Conversely, the momentum sub-score of 33 and the value sub-score of 29.3 suggest that the market is currently pricing in significant growth expectations that the top-line expansion has yet to fully validate. The absence of sentiment data leaves the stock’s near-term narrative dependent on fundamental execution rather than speculative interest. Investors should monitor whether the firm can leverage its high quality rating to accelerate revenue growth and justify its current earnings multiple throughout the remainder of the fiscal quarter.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 1.62M | $204.08M | NEW |
| D.E. Shaw David Shaw | 1.22M | $153.10M | NEW |
| Renaissance Technologies Jim Simons (founder) | 425K | $53.42M | NEW |
| Soros Fund Management George Soros (founder) | 148K | $18.68M | NEW |
| Point72 Steve Cohen | 6K | $717.2K | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros D-CA | 2026-06-16 | purchase | $1k – $15k |
| Byron Donalds R-FL | 2026-06-09 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2025-11-18 | purchase | $1k – $15k |
| Rick Larsen D-WA | 2025-10-06 | sale | $1k – $15k |
| Lisa McClain R-MI | 2025-07-22 | purchase | $1k – $15k |
| Rob Bresnahan PA | 2025-05-15 | purchase | $1k – $15k |
| Rob Bresnahan PA | 2025-04-08 | sale | $1k – $15k |
| Julie Johnson D-TX | 2025-04-01 | sale | $1k – $15k |
Zoetis Inc. is a leading animal health company that engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. It operates across seven major product categories, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. The company serves a diversified portfolio of species, encompassing livestock such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses. Zoetis Inc. holds the largest market share in the animal health industry, providing essential solutions for both production animals and pets worldwide. Its offerings support veterinarians, livestock producers, and pet owners by addressing key health needs in these sectors. Founded in 2013 and headquartered in Parsippany, New Jersey, Zoetis Inc. plays a pivotal role in advancing animal care through innovative products and services.
Earnings calendar coming soon. Subscribe to get notified when ZTS reports next.
Get earnings alerts →